Role of mitochondria in nonalcoholic fatty liver disease-from origin to propagation

Clinical Biochemistry

Volumn 45, Issue 9, 2012, Pages 610-618

  Grattagliano, Ignazio ^a   de Bari, Ornella ^a,b   Bernardo, Telma C ^c   Oliveira, Paulo J ^c   Wang, David Q H ^b   Portincasa, Piero ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Breath tests; Fatty acid beta oxidation; Mitochondria; Nonalcoholic fatty liver disease; Oxidative stress

Indexed keywords

2 OXOBUTYRIC ACID; 2 OXOISOCAPROIC ACID; ACETYL COENZYME A; ADENINE NUCLEOTIDE TRANSLOCASE; ANGIOTENSIN II; APOLIPOPROTEIN C3; CARDIOLIPIN; GLUTATHIONE; HYDROGEN PEROXIDE; LEPTIN; REACTIVE NITROGEN SPECIES; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

CELL DEATH; CELL FATE; CELL FUNCTION; CELL STRESS; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA POLYMORPHISM; DYSLIPIDEMIA; ENERGY YIELD; FATTY ACID METABOLISM; GENETIC VARIABILITY; HUMAN; HYPERTENSION; INSULIN RESISTANCE; LIPID STORAGE; LIVER CELL; LIVER METABOLISM; MITOCHONDRIAL RESPIRATION; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; CELL DEATH; CYTOPROTECTION; DISEASE PROGRESSION; FATTY ACIDS; FATTY LIVER; HEPATOCYTES; HUMANS; INTRA-ABDOMINAL FAT; LIPID METABOLISM; MICE; MITOCHONDRIA, LIVER; OXIDATIVE STRESS; RATS; RISK FACTORS;

EID: 84861230299     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.03.024     Document Type: Review

References (104)

1. Alisi A., Feldstein A.E., Villani A., Raponi M., Nobili V. Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nat Rev Gastroenterol Hepatol 2012, 9:152-161.
2. Brunt E.M. Pathology of nonalcoholic steatohepatitis. Hepatol Res 2005, 33:68-71.
3. Krawczyk M., Bonfrate L., Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol 2010, 24:695-708.
4. Kass G.E., Price S.C. Role of mitochondria in drug-induced cholestatic injury. Clin Liver Dis 2008, 12:27-51.
5. Pessayre D., Mansouri A., Haouzi D., Fromenty B. Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 1999, 15:367-373.
6. Portincasa P., Grattagliano I., Palmieri V.O., Palasciano G. Nonalcoholic steatohepatitis: recent advances from experimental models to clinical management. Clin Biochem 2005, 38:203-217.
7. Anstee Q.M., Daly A.K., Day C.P. Genetics of alcoholic and nonalcoholic fatty liver disease, semin. Liver Dis 2011, 31:128-146.
8. Merriman R.B., Aouizerat B.E., Bass N.M. Genetic influences in nonalcoholic fatty liver disease. J Clin Gastroenterol 2006, 40(Suppl. 1):S30-S33.
9. Chalasani N., Guo X., Loomba R., Goodarzi M.O., Haritunians T., Kwon S., et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 2010, 139:1567-1576.
10. Romeo S., Kozlitina J., Xing C., Pertsemlidis A., Cox D., Pennacchio L.A., et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008, 40:1461-1465.
11. Kozlitina J., Boerwinkle E., Cohen J.C., Hobbs H.H. Dissociation between APOC3 variants, hepatic triglyceride content and insulin resistance. Hepatology 2011, 53:467-474.
12. Ballestri S., Day C.P., Daly A.K. Polymorphism in the farnesyl diphosphate farnesyl transferase 1 gene and nonalcoholic fatty liver disease severity. Gastroenterology 2011, 140:1694-1695.
13. Sookoian S., Castano G.O., Burgueno A.L., Gianotti T.F., Rosselli M.S., Pirola C.J. The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. Pharmacogenet Genomics 2010, 20:1-8.
14. Palmieri V.O., Grattagliano I., Portincasa P., Palasciano G. Systemic oxidative alterations are associated with visceral adiposity and liver steatosis in patients with metabolic syndrome. J Nutr 2006, 136:3022-3026.
15. van der Poorten D., Milner K.L., Hui J., Hodge A., Trenell M.I., Kench J.G., et al. Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology 2008, 48:449-457.
16. Matsuzawa Y. The metabolic syndrome and adipocytokines. FEBS Lett 2006, 580:2917-2921.
17. Pessayre D., Fromenty B. NASH: a mitochondrial disease. J Hepatol 2005, 42:928-940.
18. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., McCullough A.J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
19. Shteyer E., Liao Y., Muglia L.J., Hruz P.W., Rudnick D.A. Disruption of hepatic adipogenesis is associated with impaired liver regeneration in mice. Hepatology 2004, 40:1322-1332.
20. Yamaguchi K., Yang L., McCall S., Huang J., Yu X.X., Pandey S.K., et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 2007, 45:1366-1374.
21. Pereira C.V., Moreira A.C., Pereira S.P., Machado N.G., Carvalho F.S., Sardao V.A., et al. Investigating drug-induced mitochondrial toxicity: a biosensor to increase drug safety?. Curr Drug Saf 2009, 4:34-54.
22. Drago I., Pizzo P., Pozzan T. After half a century mitochondrial calcium in- and efflux machineries reveal themselves. EMBO J 2011, 30:4119-4125.
23. Hodson L., Frayn K.N. Hepatic fatty acid partitioning. Curr Opin Lipidol 2011, 22:216-224.
24. Jump D.B., Botolin D., Wang Y., Xu J., Christian B., Demeure O. Fatty acid regulation of hepaticgene transcription. J Nutr 2005, 135:2503-2506.
25. Nakamura M.T., Cheon Y., Li Y., Nara T.Y. Mechanisms of regulation of gene expression by fatty acids. Lipids 2004, 39:1077-1083.
26. Lopaschuk G.D. Targets for modulation of fatty acid oxidation in the heart. Curr Opin Investig Drugs 2004, 5:290-294.
27. Schreurs M., Kuipers F., van der Leij F.R. Regulatory enzymes of mitochondrial beta-oxidation as targets for treatment of the metabolic syndrome. Obes Rev 2010, 11:380-388.
28. Kompare M., Rizzo W.B. Mitochondrial fatty-acid oxidation disorders. Semin Pediatr Neurol 2008, 15:140-149.
29. Fromenty B., Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995, 67:101-154.
30. Chen Y., Hozawa S., Sawamura S., Sato S., Fukuyama N., Tsuji C., et al. Deficiency of inducible nitric oxide synthase exacerbates hepatic fibrosis in mice fed high-fat diet. Biochem Biophys Res Commun 2005, 326:45-51.
31. Klatt P., Lamas S. Regulation of protein function by S-glutathiolation in response to oxidative and nitrosative stress. Eur J Biochem 2000, 267:4928-4944.
32. Begriche K., Massart J., Robin M.A., Borgne-Sanchez A., Fromenty B. Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. J Hepatol 2011, 54:773-794.
33. Diogo C.V., Grattagliano I., Oliveira P.J., Bonfrate L., Portincasa P. Re-wiring the circuit: mitochondria as a pharmacological target in liver disease. Curr Med Chem 2011, 18:5448-5465.
34. Grattagliano I., Russmann S., Diogo C.V., Bonfrate L., Oliveira P.J., Wang D.Q., et al. Mitochondria in chronic liver disease. Curr Drug Targets 2011, 12:879-893.
35. Krahenbuhl S. Alterations in mitochondrial function and morphology in chronic liver disease: pathogenesis and potential for therapeutic intervention. Pharmacol Ther 1993, 60:1-38.
36. Roberts R.A., Smith R.A., Safe S., Szabo C., Tjalkens R.B., Robertson F.M. Toxicological and pathophysiological roles of reactive oxygen and nitrogen species. Toxicology 2010, 276:85-94.
37. Petrosillo G., Matera M., Moro N., Ruggiero F.M., Paradies G. Mitochondrial complex I dysfunction in rat heart with aging: critical role of reactive oxygen species and cardiolipin. Free Radic Biol Med 2009, 46:88-94.
38. Kagan V.E., Bayir H.A., Belikova N.A., Kapralov O., Tyurina Y.Y., Tyurin V.A., et al. Cytochrome c/cardiolipin relations in mitochondria: a kiss of death. Free Radic Biol Med 2009, 46:1439-1453.
39. Radi R., Cassina A., Hodara R., Quijano C., Castro L. L, Peroxynitrite reactions and formation in mitochondria. Free Radic Biol Med 2002, 33:1451-1464.
40. Sanyal A.J., Campbell-Sargent C., Mirshahi F., Rizzo W.B., Contos M.J., Sterling R.K., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001, 120:1183-1192.
41. Ricchelli F., Sileikyte J., Bernardi P. Shedding light on the mitochondrial permeability transition. Biochim Biophys Acta 2011, 1807:482-490.
42. Jaeschke H., McGill M.R., Ramachandran A. Oxidant stress, mitochondria, and cell death mechanisms in drug-induced liver injury: lessons learned from acetaminophen hepatotoxicity. Drug Metab Rev 2012, 44:88-106.
43. Nakagawa Y., Suzuki T., Kamimura H., Nagai F. Role of mitochondrial membrane permeability transition in N-nitrosofenfluramine-induced cell injury in rat hepatocytes. Eur J Pharmacol 2006, 529:33-39.
44. Trost L.C., Lemasters J.J. Role of the mitochondrial permeability transition in salicylate toxicity to cultured rat hepatocytes: implications for the pathogenesis of Reye's syndrome. Toxicol Appl Pharmacol 1997, 147:431-441.
45. Mingatto F.E., dos Santos A.C., Rodrigues T., Pigoso A.A., Uyemura S.A., Curti C. Effects of nimesulide and its reduced metabolite on mitochondria. Br J Pharmacol 2000, 131:1154-1160.
46. Singh B.K., Tripathi M., Pandey P.K., Kakkar P. Nimesulide aggravates redox imbalance and calcium dependent mitochondrial permeability transition leading to dysfunction in vitro. Toxicology 2010, 275:1-9.
47. Tay V.K., Wang A.S., Leow KY K.Y., Ong M.M., Wong K.P., Boesterli U.A. Mitochondrial permeability transition as a source of superoxide anion induced by the nitroaromatic drug nimesulide in vitro. Free Radic Biol Med 2005, 39:949-959.
48. Moreno A.J., Oliveira P.J., Nova C.D., Alvaro A.R., Moreira R.A., Santos S.M., et al. Unaltered hepatic oxidative phosphorylation and mitochondrial permeability transition in Wistar rats treated with nimesulide: relevance for nimesulide toxicity characterization. J Biochem Mol Toxicol 2007, 21:53-61.
49. Baines C.P., Kaiser R.A., Purcell N.H., Blair N.S., Osinska H., Hambleton M.A., et al. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 2005, 434:658-662.
50. Kim J.S., He L., Lemasters J.J. Mitochondrial permeability transition: a common pathway to necrosis and apoptosis. Biochem Biophys Res Commun 2003, 304:463-470.
51. Russmann S., Kullak-Ublick G.A., Grattagliano I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr Med Chem 2009, 16:3041-3053.
52. Kroemer G., Reed J.C. Mitochondrial control of cell death. Nat Med 2000, 6:513-519.
53. Pessayre D., Fromenty B., Mansouri A. Mitochondrial injury in steatohepatitis. Eur J Gastroenterol Hepatol 2004, 16:1095-1105.
54. Rolo A.P., Teodoro J.S., Palmeira C.M. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic Biol Med 2012, 52:59-69.
55. Silva M.F., Aires C.C., Luis P.B., Ruiter J.P., Ijlst L., Duran M., et al. Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis 2008, 31:205-216.
56. Lu M.Y., Huang J.F., Liao Y.C., Bai R.K., Trieu R.B., Chuang W.L., et al. Mitochondrial polymorphism 12361A>G is associated with nonalcoholic fatty liver disease. Transl Res 2012, 159:58-59.
57. Sabbagha N.G., Kao H.J., Yang C.F., Huang C.C., Lin W.D., Tsai F.J., et al. Alternative splicing in Acad8 resulting a mitochondrial defect and progressive hepatic steatosis in mice. Pediatr Res 2011, 70:31-36.
58. Mandel H., Hartman C., Berkowitz D., Elpeleg O.N., Manov I., Iancu T.C. The hepatic mitochondrial DNA depletion syndrome: ultrastructural changes in liver biopsies. Hepatology 2001, 34:776-784.
59. de Alwis N., Aithal G., Bugianesi E., Leathart J., Hudson G., Pyle A., et al. Mitochondrial DNA does not contribute to the heritability of non-alcoholic fatty liver disease. Mitochondrion 2011, 11:234-235.
60. Pereira C.V., Lebiedzinska M., Wieckowski M.R., Oliveira P.J. Regulation and protection of mitochondrial physiology by sirtuins. Mitochondrion 2012, 12:66-76.
61. Hirschey M.D., Shimazu T., Goetzman E., Jing E., Schwer B., Lombard D.B., et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 2010, 464:121-125.
62. Hirschey M.D., Shimazu T., Jing E., Grueter C.A., Collins A.M., Aouizerat B., et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell 2011, 44:177-190.
63. Kendrick A.A., Choudhury M., Rahman S.M., McCurdy C.E., Friederich M., Van Hove J.L., et al. Fatty liver is associated with reduced SIRT3 activity and mitochondrial protein hyperacetylation. Biochem J 2011, 433:505-514.
64. Colak Y., Ozturk O., Senates E., Tuncer I., Yorulmaz E., Adali G., et al. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit 2011, 17:HY5-HY9.
65. Grattagliano I., Caraceni P., Portincasa P., Domenicali M., Palmieri V.O., Trevisani F., et al. Adaptation of subcellular glutathione detoxification system to stress conditions in choline-deficient diet induced rat fatty liver. Cell Biol Toxicol 2003, 19:355-366.
66. Donnelly K.L., Smith C.I., Schwarzenberg S.J., Jessurun J., Boldt M.D., Parks E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 2005, 115:1343-1351.
67. Ip E., Farrell G.C., Robertson G., Hall P., Kirsch R., Leclercq I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology 2003, 38:123-132.
68. Di Paola M., Lorusso M. Interaction of free fatty acids with mitochondria: coupling, uncoupling and permeability transition. Biochim Biophys Acta 2006, 1757:1330-1337.
69. Gambino R., Musso G., Cassader M. Redox balance in the pathogenesis of nonalcoholic fatty liver disease: mechanisms and therapeutic opportunities. Antioxid Redox Signal 2011, 15:1325-1365.
70. Sluse F.E., Jarmuszkiewicz W., Navet R., Douette P., Mathy G., Sluse-Goffart C.M. Mitochondrial UCPs: new insights into regulation and impact. Biochim Biophys Acta 2006, 1757:480-485.
71. Mailloux R.J., Harper M.E. Uncoupling proteins and the control of mitochondrial reactive oxygen species production. Free Radic Biol Med 2011, 51:1106-1115.
72. Klaus S., Keipert S., Rossmeisl M., Kopecky J. Augmenting energy expenditure by mitochondrial uncoupling: a role of AMP-activated protein kinase. Genes Nutr 2011, [Epub ahead of print].
73. Ricquier D. Respiration uncoupling and metabolism in the control of energy expenditure. Proc Nutr Soc 2005, 64:47-52.
74. Negre-Salvayre A., Hirtz C., Carrera G., Cazenave R., Troly M., Salvayre R., et al. A role for uncoupling protein-2 as a regulator of mitochondrial hydrogen peroxide generation. FASEB J 1997, 11:809-815.
75. Dalen K.T., Ulven S.M., Arntsen B.M., Solaas K., Nebb H.I. PPARalpha activators and fasting induce the expression of adipose differentiation-related protein in liver. J Lipid Res 2006, 47:931-943.
76. Tilg H., Hotamisligil G.S. Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance. Gastroenterology 2006, 131:934-945.
77. Tsochatzis E., Papatheodoridis G.V., Archimandritis A.J. The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol 2006, 101:2629-2640.
78. Caldwell S.H., Swerdlow R.H., Khan E.M., Iezzoni J.C., Hespenheide E.E., Parks J.K., et al. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999, 31:430-434.
79. Perez-Carreras M., Del Hoyo P., Martin M.A., Rubio J.C., Martin A., Castellano G., et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003, 38:999-1007.
80. Yang S., Zhu H., Li Y., Lin H., Gabrielson K., Trush M.A., et al. Mitochondrial adaptations to obesity-related oxidant stress. Arch Biochem Biophys 2000, 378:259-268.
81. Tilg H., Moschen A.R. Relevance of TNF-alpha gene polymorphisms in nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2011, 5:155-158.
82. Garcia-Ruiz C., Fernandez-Checa J.C. Mitochondrial glutathione: hepatocellular survival-death switch. J Gastroenterol Hepatol 2006, 21(Suppl. 3):S3-S6.
83. Grattagliano I., Portincasa P., Palmieri V.O., Palasciano G. Mutual changes of thioredoxin and nitrosothiols during biliary cirrhosis: results from humans and cholestatic rats. Hepatology 2007, 45:331-339.
84. Grattagliano I., Caraceni P., Calamita G., Ferri D., Gargano I., Palasciano G., et al. Severe liver steatosis correlates with nitrosative and oxidative stress in rats. Eur J Clin Invest 2008, 38:523-530.
85. Wei Y., Clark S.E., Thyfault J.P., Uptergrove G.M., Li W., Whaley-Connell A.T., et al. Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats. Am J Pathol 2009, 174:1329-1337.
86. Begriche K., Igoudjil A., Pessayre D., Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006, 6:1-28.
87. Vendemiale G., Grattagliano I., Caraceni P., Caraccio G., Domenicali M., Dall'Agata M., et al. Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: effect of the nutritional status. Hepatology 2001, 33:808-815.
88. Petrosillo G., Portincasa P., Grattagliano I., Casanova G., Matera M., Ruggiero F.M., et al. Mitochondrial dysfunction in rat with nonalcoholic fatty liver Involvement of complex I, reactive oxygen species and cardiolipin. Biochim Biophys Acta 2007, 1767:1260-1267.
89. Schlame M., Ren M. The role of cardiolipin in the structural organization of mitochondrial membranes. Biochim Biophys Acta 2009, 1788:2080-2083.
90. Teodoro J.S., Rolo A.P., Duarte F.V., Simoes A.M., Palmeira C.M. Differential alterations in mitochondrial function induced by a choline-deficient diet: understanding fatty liver disease progression. Mitochondrion 2008, 8:367-376.
91. Thyfault J.P., Rector R.S., Uptergrove G.M., Borengasser S.J., Morris E.M., Wey Y., et al. Rats selectively bred for low aerobic capacity have reduced hepatic mitochondrial oxidative capacity and susceptibility to hepatic steatosis and injury. J Physiol 2009, 587:1805-1816.
92. Masuo Y., Imai T., Shibato J., Hirano M., Jones O.A., Maguire M.L., et al. Omic analyses unravels global molecular changes in the brain and liver of a rat model for chronic Sake (Japanese alcoholic beverage) intake. Electrophoresis 2009, 30:1259-1275.
93. Griffin J.L., Nicholls A.W. Metabolomics as a functional genomic tool for understanding lipid dysfunction in diabetes, obesity and related disorders. Pharmacogenomics 2006, 7:1095-1107.
94. Grattagliano I., Lauterburg B.H., Palasciano G., Portincasa P. 13C-breath tests for clinical investigation of liver mitochondrial function. Eur J Clin Invest 2010, 40:843-850.
95. 13C-methionine breath test in patients with macrovesicular steatosis and patients with cirrhosis. Med Sci Monit 2003, 9:CR6-CR11.
96. Mion F., Rousseau M., Brazier J.L., Minaire Y. Human hepatic macrovesicular steatosis: a noninvasive study of mitochondrial ketoisocaproic acid decarboxylation. Metabolism 1995, 44:699-700.
97. Portincasa P., Grattagliano I., Lauterburg B.H., Palmieri V.O., Palasciano G., Stellaard F. Liver breath tests non-invasively predict higher stages of non-alcoholic steatohepatitis. Clin Sci (Lond) 2006, 111:135-143.
98. Parra D., Gonzalez A., Martinez J.A., Labayen I., Diez N. In vivo assessment of the mitochondrial response to caloric restriction in obese women by the 2-keto[1-C]isocaproate breath test. Metabolism 2003, 52:463-467.
99. McCarty M.F. Full-spectrum antioxidant therapy featuring astaxanthin coupled with lipoprivic strategies and salsalate for management of non-alcoholic fatty liver disease. Med Hypotheses 2011, 77:550-556.
100. Palasciano G., Moschetta A., Palmieri V.O., Grattagliano I., Iacobellis G., et al. Non-alcoholic fatty liver disease in the metabolic syndrome. Curr Pharm Des 2007, 13:2193-2198.
101. Hebbard L., George J. Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2011, 8:35-44.
102. Zhang H., Wang Y., Zhang J., Potter B.J., Sowers J.R., Zhang C. Bariatric surgery reduces visceral adipose inflammation and improves endothelial function in type 2 diabetic mice. Arterioscler Thromb Vasc Biol 2011, 31:2063-2069.
103. Santos M.J., Fonseca J.E. Metabolic syndrome, inflammation and atherosclerosis - the role of adipokines in health and in systemic inflammatory rheumatic diseases. Acta Reumatol Port 2009, 34:590-598.
104. Sanyal A.J. NASH: a global health problem. Hepatol Res 2011, 41:670-674.